Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Aprea Therapeutics in connection with its EUR 50 million financing
Mandate

Vinge has advised Aprea Therapeutics in connection with its EUR 50 million financing

December 04, 2018 Banking and Finance

Aprea Therapeutics AB, with headquarters in Stockholm (Solna), is a biotechnology company focused on the discovery and development of new cancer drugs reactivating the tumour suppressor protein p53. 

Vinge has advised Aprea Therapeutics in connection with its EUR 50 million series C financing round, led by the Redmile Group and with participation by the new investor Rock Springs Capital and the existing shareholders 5AM Ventures, Versant Ventures, HealthCap, Sectoral Asset Management, Karolinska Development AB.

Vinge’s team consisted of Kristina Ekberg, Peter Issa and Tove Lövgren Frisk. 

Related

Vinge advises Workday, Inc. on its $1.1 billion acquisition of Sana Labs

 Vinge, together with Orrick Herrington & Sutcliffe, has advised Workday, Inc. (NASDAQ: WDAY) (“Workday”) on its acquisition of all shares in Sana Labs AB.
September 16, 2025

Vinge advises on the sale of ArmaTech to Defensor Group

 Vinge has advised on the sale of ArmaTech i Kungsbacka AB (“ArmaTech”) to the newly formed defence group Defensor Group AB (“Defensor”).
September 16, 2025

Vinge advisor in connection with Klarna's IPO on the New York Stock Exchange

 Vinge, together with Latham & Watkins, acted as advisor to bookrunners and managers in connection with the listing of Klarna, the global digital bank and provider of flexible payment solutions, on the New York Stock Exchange.
September 15, 2025